DailyIQ
|
Last updated4 minutes ago

TEM·Tempus AI Inc. Class A

$68.32
+0.10 (+0.15%)
Overnight$66.90-1.42 (-2.08%)
High
$71.35
Open
$67.00
Market Cap
12.31B
52W High
$97.25
Low
$66.21
P. Close
$68.32
P/E
-
52W Low
$40.77
Fwd P/E
-1450.22
DailyIQ Est.
$75.94
Inst. Ownership
28.2%
Short Interest
14.08%
Days to Cover
3.2
Technical Score (1D)
6
BEARISH
News Sentiment
64
BULLISH
On Oct 13, TEM announced that its subsidiary Ambry Genetics had launched GenomeNext™ and GenomeReveal™, a whole‑genome sequencing platform designed to improve diagnostic rates for rare diseases. The new solution incorporates a pangenome reference to enhance variant detection across diverse ancestries and combines RNA analysis to aid interpretation of DNA findings. By offering ongoing reanalysis, the platform aims to shorten the diagnostic odyssey for patients and families. The introduction of GenomeNext™ and GenomeReveal™ expands TEM’s clinical genomics portfolio and strengthens its position in precision medicine. The announcement highlighted the company’s focus on advancing genomic tools that can deliver more accurate and timely diagnoses for rare disease patients.
LOW TARGET
$35 -48.8%
2 analysts
MEAN TARGET
$74 +7.7%
12 analysts
HIGH TARGET
$100 +46.4%
9 analysts
PRICE RANGE
$35.00 - $100.00
SB / B / H / S / SS
6/7/8/1/1
DAILYIQ EST.
$75.94 (+11.2%)
Bought (1Y)
0 shares
$0
Sold (1Y)
1,724,414 shares
$104.3M
Schoenherr Thomas EdwardCEO, Diagnostics
Sell10,281 shares2026-09-25
LEFKOFSKY ERIC PCEO and Chairman
Sell160 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell14,042 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell29,367 shares2026-09-22
LEFKOFSKY ERIC PCEO and Chairman
Sell6,431 shares2026-09-22
View full insider trading history →
38/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-19.3%
Revenue CAGR
58.3%
Current Ratio
3.13x
Return on Equity
-49.9%
View full financials →

EPS

EstBeatMiss
$-0.19$-0.16$-0.13$-0.09$-0.06Q3'25Q3'26
QtrEstActual+/−
Q3'26$-0.08 - -
Q3'25$-0.18$-0.11+37.3%

Revenue

EstBeatMiss
$322M$348M$374M$400M$426MQ3'25Q3'26
QtrEstActual+/−
Q3'26$414M - -
Q3'25 - $334M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TEM Stock Snapshot

BEARISH6/100
$66.90−$1.42 (2.1%)
Market cap
12.31B
Day range
$66.21 – $71.35
News sentiment
64/100 · Bullish
Analyst target
$73.56 (+10.0%)
Consensus
Hold · 23 analysts
52-week range+64.1% off low · -31.2% from high
$40.77$97.25
Price $66.90 DailyIQ Est. $75.94

TEM's technical picture is under pressure, with momentum working against price. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What TEM's own history says about today's numbers

Realized volatility (21d)
85.5% 56th pct
vs 200-day average
+20.7%
Up days (1y)
45%

Tempus AI Inc. Class A is currently running 85.5% annualised volatility over the last 21 sessions. Measured against TEM's own 2 years of daily returns rather than a market-wide average, that is the 56th percentile — close to its own typical level, against a typical reading of 80.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

Price sits +20.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 72nd percentile — a somewhat wider gap than its own norm. Over the past year TEM closed higher on 45% of sessions, and it is currently 2 sessions into a rising streak.

Overnight risk is measurable too: TEM has opened more than 2% away from the prior close in 66 of 584 sessions (11.3% of the time), with the largest gaps running +16.1% and -7.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 585 daily closes between 2024-06-14 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against TEM's own 2-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of TEM's sector?

Tempus AI Inc. Class A sits in the Software sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Software industry group, TEM ranks 3rd of 15 tracked industries, weakening.

Sector rank
#5 of 12
Sector state
Weakening
Sector rotation score
73
Industry rank
#3 of 15

Options Market

What is the options market pricing for TEM?

CallsPuts

For Tempus AI Inc. Class A's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.72), with at-the-money implied volatility around 96.9%. The options market is pricing roughly a ±9.6% move by that expiry — a range of about $74.48–$90.30.

Put/call ratio (2026-10-16)
0.72
ATM implied volatility
96.9%
Total open interest
41,515
Expected move by 2026-10-16
±9.6% ($74.48–$90.30)

Analyst Rating Changes

Are analysts turning bullish or bearish on TEM?

Canaccord Genuity most recently reiterated its rating on Tempus AI Inc. Class A to Buy on Oct 12, 2026 with a price target of $95 (from $80). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Canaccord Genuity — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 12, 2026Canaccord GenuityMaintainedBuy$80 → $95
Oct 1, 2026GuggenheimMaintainedBuy$65 → $92
Sep 21, 2026Goldman SachsInitiatedNeutral$75
Sep 11, 2026HC Wainwright & Co.MaintainedBuy$56 → $66
Sep 9, 2026UBSInitiatedNeutral$70
Sep 8, 2026Rothschild & CoInitiatedNeutral$67
Sep 8, 2026Roth CapitalInitiatedNeutral$67
Sep 2, 2026Cantor FitzgeraldInitiatedOverweight$80
Sep 1, 2026Piper SandlerUpgradeNeutral → Overweight$56 → $76
Aug 31, 2026Freedom Capital MarketsMaintainedHold$51 → $73
Aug 20, 2026BTIGMaintainedBuy$70 → $80
Aug 4, 2026Piper SandlerMaintainedNeutral$58 → $56

ETF holders

ETFs holding TEM

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
TEM, through its subsidiary Ambry Genetics, introduced GenomeNext™ and GenomeReveal™ as a comprehensive whole genome sequencing platform aimed at improving diagnostic rates for rare diseases. The solution integrates a pangenome reference to enhance variant detection across diverse ancestries and combines RNA analysis to aid interpretation of DNA findings. By offering ongoing reanalysis, the platform seeks to reduce the diagnostic odyssey for patients and families, potentially expanding TEM’s clinical genomics portfolio and strengthening its position in precision medicine.
What did this article say?
Canaccord Genuity’s analyst Kyle Mikson upgraded his recommendation for Tempus AI to a Buy and increased the price target from $80 to $95. The upgrade reflects confidence in the company’s AI‑driven diagnostics platform and its growing market traction. The higher target suggests that the firm expects continued revenue growth and margin expansion in the near term.
What did this article say?
Tempus AI (TEM) posted a 56.9% share price gain over the six months ending October 8, 2026, after announcing its first quarterly profit on July 30. The earnings milestone followed a trajectory of narrowing losses documented in 2025 filings, confirming the company’s earlier claim of moving toward cash flow and adjusted breakeven. The stock’s rally began more than three months before the profit announcement, suggesting market participants had already priced in the positive trajectory. The profit and trend toward breakeven represent a confirmed material upside for TEM, likely boosting investor confidence and valuation.
What did this article say?
Tempus AI reported a 28% increase in Data and Applications revenue to $93.2 million in the second quarter, driven by expanding pharmaceutical customer usage of its multimodal data and AI solutions. The Insights segment grew 36%, reflecting broader adoption of Tempus' data licensing and modeling services. These results reinforce the company’s positioning in the rapidly expanding AI‑in‑healthcare market and support a positive outlook for its financial performance.
What did this article say?
On October 7, TEM announced it had broadened its multi‑year partnership with Moderna and Merck to advance the potential commercialization of intismeran autogene, an individualized cancer therapy being evaluated with Keytruda in melanoma and other malignancies. The expanded agreement gives TEM responsibility for tumor tissue and blood sample collection, transfer for sequencing, and next‑generation sequencing services to support therapy design and manufacturing. No financial terms were disclosed, but the move positions TEM as a key collaborator in the development of personalized oncology treatments.
What did this article say?
On October 6, the U.S. Food and Drug Administration granted 510(k) clearance to Tempus AI’s ECG‑MR, an AI system for early detection of mitral regurgitation. The approval coincided with a 9% intraday rise in TEM shares, lifting the price to $83.55 and contributing to a 29% month‑to‑date gain. The clearance signals regulatory validation for the company’s product pipeline and may enhance investor confidence, although the year‑to‑date shareholder return remains negative. The move underscores TEM’s progress toward commercial deployment of its AI diagnostics platform.
What did this article say?
Tempus AI (TEM) obtained 510(k) FDA clearance for its Tempus ECG-MR and Tempus ECG-PH AI‑enabled ECG analysis tools, expanding its cardiovascular portfolio. The new products detect moderate or severe mitral regurgitation and pulmonary hypertension from standard 12‑lead ECGs, providing binary diagnostic outputs. The AI‑ECG market is projected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a 19.3% CAGR, positioning TEM to capture a larger share of this expanding segment.
What did this article say?
Tempus AI, Inc. (NASDAQ: TEM) announced that 13 abstracts were accepted for presentation at the European Society for Medical Oncology Congress 2026. The abstracts covered solid tumors such as prostate, breast, NSCLC, renal cell carcinoma, and gynecologic cancers, showcasing research on cancer biology, treatment response, and patient outcomes. The company highlighted its AI-enabled technology and product offerings, including Tempus Lens and Tempus One, at booths #1068 and #1069. These presentations aim to inform biomarker development, patient stratification, and clinical trial design.
What did this article say?
Guggenheim analyst Subbu Nambi maintained a Buy rating on Tempus AI (NASDAQ:TEM) and raised the price target from $65 to $92. The upgrade reflects confidence in the company’s growth prospects and valuation. The move signals a positive outlook for investors and may support the stock’s price trajectory.
What did this article say?
Analysts warned that Personalis shareholders remain exposed to downside in TEM shares following the merger, with limited upside beyond a $48.42 threshold. The report highlighted that Personalis’s standalone value is less relevant, as the merger’s impact on TEM stock is the primary concern. Investors were cautioned that the merger could constrain further appreciation of TEM shares.

Technical Analysis

Real-time indicators across multiple timeframes

6
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $2.92B combined position · 16 adding, 8 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy10,258,6215.75%$605.77M2026-01-29
BlackRock, Inc.▼ Sell8,291,0534.65%$480.30M2026-08-07
Baillie Gifford & Co▼ Sell8,190,1334.59%$474.45M2026-08-06
JPMorgan Chase & Co▲ Buy4,989,0622.80%$291.22M2026-08-12
Goldman Sachs Group Inc▲ Buy3,761,6662.11%$217.91M2026-08-14
Morgan Stanley▲ Buy3,652,1362.05%$211.57M2026-08-13
Citadel Advisors LLC▲ Buy2,512,4011.41%$145.54M2026-09-02
Geode Capital Management, LLC▲ Buy2,092,5191.17%$121.25M2026-08-12
Bank of America Corp▲ Buy1,917,7721.08%$111.10M2026-08-14
Norges Bank▲ Buy975,3020.55%$56.50M2026-08-12
Susquehanna International Group, LLP▲ Buy880,5560.49%$51.01M2026-08-14
Northern Trust Corp▲ Buy556,9250.31%$32.26M2026-08-13
Wellington Management Group LLP▼ Sell390,2410.22%$22.61M2026-08-14
Wells Fargo & Company▼ Sell320,7240.18%$18.58M2026-08-14
Citigroup Inc▲ Buy232,4530.13%$13.47M2026-08-03
Marshall Wace, LLP▼ Sell207,3730.12%$12.01M2026-08-13
Invesco Ltd.▼ Sell200,9200.11%$11.64M2026-08-14
Ares Management LLC• Hold164,3830.09%$9.52M2026-08-14
ExodusPoint Capital Management, LP▲ Buy147,2250.08%$8.53M2026-08-14
Millennium Management LLC▼ Sell146,1400.08%$8.47M2026-08-14
Temasek Holdings (Private) Ltd▲ Buy99,3160.06%$5.75M2026-08-07
FMR LLC (Fidelity)▲ Buy71,3120.04%$4.13M2026-08-13
AQR Capital Management LLC▲ Buy69,7440.04%$4.03M2026-08-14
Two Sigma Investments, LP▼ Sell63,8640.04%$3.70M2026-08-14
Gotham Asset Management, LLC▲ Buy47,6030.03%$2.76M2026-08-14
Q2 2026 flow:8.98M sh bought ($520.22M)2.81M sh sold ($162.57M)net +6.17M sh (+$357.65M)
View full institutional holdings history →

Discover More

BR
Broadridge Financial Solutions, Inc.
$164.90
-2.00%
TTWO
Take-Two Interactive Software, Inc.
$199.05
-1.07%
CRM
Salesforce, Inc.
$234.20
-0.75%
MDB
MongoDB
$353.50
-0.80%
DDOG
Datadog Inc.
$263.34
-2.24%
VRSK
Verisk Analytics, Inc.
$180.58
-0.03%
CDNS
Cadence Design Systems, Inc.
$327.01
-0.75%
INTU
Intuit Inc.
$306.89
-1.15%
CSGP
CoStar Group, Inc.
$30.26
+0.46%
CTSH
Cognizant Technology Solutions Corporation
$62.47
-0.05%